Our experience
A proven track record of delivering strategic clarity and measurable value across the life science landscape.
By the numbers
With over 40 years of combined experience, Tulevik brings a wealth of knowledge across the life sciences value chain.
40+
years combined expertise
125+
transactions directed by our principals
4 continents
North America, Europe, Latin America, Asia
Where we work
Coverage across the life sciences ecosystem, from discovery through distribution.
Pharma and biotech
Small molecule and biologics manufacturers assessing acquisitions, carve-outs, and manufacturing network decisions from clinical supply through commercial scale.
Advanced therapies
Cell and gene therapy developers and manufacturers navigating capacity decisions, partner selection, and a rapidly consolidating CDMO landscape.
CDMOs and pharma services
Our deepest coverage. Contract manufacturers, analytical laboratories, and service providers — on both the buy side and the sell side.
Compounding pharmacies
503B outsourcing facilities and compounding operations, where sterile capability and inspection history drive both valuation and deal risk.
Consumer health
OTC, supplement, and personal care manufacturing — including large-scale liquid, topical, and packaging assets.
Digital health
Software and data businesses supporting clinical and commercial operations, assessed against the same commercial evidence as physical assets.
MedTech
Device and diagnostics manufacturers, evaluated for facility capability, quality systems, and transaction readiness.
Selected experience
Currently advising on two sell-side manufacturing divestitures, both in confirmatory diligence.
Deal intelligence
OTC liquid manufacturing acquisition search
Retained to find a large-scale liquid manufacturing site. Screened 200+ FDA-registered liquid and topical facilities across the US and Canada against a defined technical specification, prioritised 60+, shortlisted 10+ through confidential outreach and site visits, and qualified four actionable targets to a single recommendation.
207 screened · 12 site-visited · 1 recommended
Deal intelligence
Platform acquisition strategy
Evaluated a universe of 700+ companies to define acquisition criteria, test platform theses, and build a prioritised target list for a buy-and-build strategy.
700+ companies screened to a ranked platform thesis
Curated M&A advisory
Aseptic fill-finish acquisition search
Retained to identify sterile manufacturing capability. Identified 230+ aseptic operations across the US and Canada, filtered to 2+ prioritised sites against client technical criteria, qualified six actionable targets, and benchmarked 15+ comparable aseptic facility transactions.
231 operations screened · 22 prioritised sites · 6 actionable targets
· transaction completed
Curated M&A advisory
Sell-side divestiture programme
Ran a structured sell-side process for a manufacturing asset, engaging a buyer pool of 300+ and profiling 50+ high-priority prospects to build competitive tension deliberately.
300+ buyers engaged · 50+ prospects profiled
Insight-driven market entry
GMP cold storage market assessment
Assessed the US GMP cold storage market across various temperature regimes sizing demand, mapping national and regional providers, profiling end-user requirements, and modelling revenue. Delivered a ranked entry recommendation with configuration and redundancy guidance.
Four temperature segments assessed · ranked entry recommendation delivered
Embedded capability
Two-week confirmatory diligence
Engaged mid-process to deliver fast-turnaround market intelligence and site deep dives, drawing on subject-matter experts to surface red flags and upside ahead of a committee decision.
Two-week turnaround inside a live process